-
Psst! Need a Simple and Reliable Eye Tracker for Your Brain Studies?
Clinical Research News | A mechanical engineer at the University of Houston is seeking physician collaborators with a research need for a small but sensitive wearable eye-tracking system to provide continuous data on human brain activity. The need was suggested by a survey of the literature, which found that a shortage of data coming from devices used in supervised clinical settings was resulting in inconclusive correlations study after study.
Oct 15, 2024
-
Catching Up With Jill Pellegrino, Now Leading AutoCruitment
Clinical Research News | For as long as most people can remember, patient enrollment into clinical trials has been abysmal—so much so that 80% of studies don’t finish on time and 55% end due to low accrual rates. The underlying issue is overreliance on study sites to find participants on their own.
Oct 10, 2024
-
CluePoints Launches Medical & Safety Review (MSR) Software
Clinical Research News | CluePoints has launched its Medical & Safety Review (MSR) tool that aims to simplify and streamline the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history.
Oct 9, 2024
-
Curing Data Collection Woes Could Take a Village
Clinical Research News | The average clinical trial generates three times as much data as it did a decade ago, and yet there are no standards in place for how that information should be collected. That’s a big problem for many reasons, not the least of which is that drug developers may be missing key insights about the way interventions are working in individuals and across populations.
Oct 8, 2024
-
Study Aims to Resolve Variants of Uncertain Significance
Clinical Research News | A pioneering study led by Dr. Lachlan Jolly at the University of Adelaide’s Neurobiology Research Group is transforming genetic diagnostics by resolving variants of uncertain significance (VUS) using skin samples. Many patients with VUS lack a definitive diagnosis because RNA from disease-causing genes often can't be extracted from accessible tissues like blood or skin.
Oct 3, 2024
-
Scope of Things: Trial Planning Skews Conclusions, AI Diversity Help, News of the Month
Clinical Research News | In this month’s episode of the Scope of Things, host Deborah Borfitz covers everything you need to know about a pending launch of a large treatment trial for Graves’ disease, a recruitment campaign for a diagnostic tampon, Walgreens and BARDA’s new partnership, how eligibility criteria has been excluding people of African or Middle Eastern descent from cancer studies, and more.
Oct 2, 2024
-
Follow the Money: GPCR Targets, Upacicalcet, AAV-Delivered Cancer Immunotherapy, More
Clinical Research News | Superluminal Medicines is focusing on supporting the progression of their lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets; Pathalys Pharma wraps up upacicalcet clinical trials; Vironexis anticipates initiating patient enrollment of a Phase 1/2 trial of VNX-101 in the fourth quarter of 2024, which will mark the first-ever clinical trial of an AAV-delivered cancer immunotherapy; and more.
Sep 26, 2024
-
AstraZeneca, Moffitt Cancer Center Partner, Firefly Neuroscience Advances AI Tech, More
Clinical Research News | Moffitt Cancer Center announced a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell and T cell receptor therapies; Firefly Neuroscience announced the advancement of its artificial intelligence-powered Brain Network Analytics (BNA) technology; and more.
Sep 25, 2024
-
PCORI Offers $100 Million For Youth Research, Children’s Health Promotion
Clinical Research News | PCORI announced earlier this month that they are inviting proposals through eight new funding opportunities. These include three PCORI Funding Announcements for patient-centered comparative clinical effectiveness research (CER). Letters of intent are due October 1, 2024, and applications will be accepted until January 14, 2025.
Sep 24, 2024